WESPAC Advisors SoCal’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.03M Buy
858
+185
+27% +$189K 0.18% 81
2026
Q1
$619K Sell
673
-2
-0.3% -$2.03K 0.13% 87
2025
Q4
$725K Buy
675
+12
+2% +$11.5K 0.15% 82
2025
Q3
$506K Sell
663
-46
-6% -$34.2K 0.1% 88
2025
Q2
$553K Sell
709
-116
-14% -$90.1K 0.12% 81
2025
Q1
$681K Sell
825
-1,035
-56% -$861K 0.18% 69
2024
Q4
$1.44M Sell
1,860
-14,816
-89% -$12.3M 0.32% 60
2024
Q3
$14.8M Buy
16,676
+1,290
+8% +$1.16M 3.42% 9
2024
Q2
$13.9M Buy
15,386
+938
+6% +$750K 3.5% 7
2024
Q1
$11.2M Buy
14,448
+565
+4% +$402K 2.94% 10
2023
Q4
$8.09M Buy
+13,883
New +$8.1M 2.36% 15
2016
Q4
Sell
-300
Closed -$24.1K 273
2016
Q3
$24.1K Hold
300
0.02% 140
2016
Q2
$23.6K Hold
300
0.02% 151
2016
Q1
$21.6K Sell
300
-500
-63% -$37.8K 0.02% 149
2015
Q4
$67K Buy
+800
New +$66.4K 0.04% 112

Other funds holding LLY

WESPAC Advisors SoCal's LLY Position: Q2 2026 in Review

WESPAC Advisors SoCal increased its Eli Lilly (LLY) stake by 27% in Q2 2026, buying an estimated $189K and bringing the position to 858 shares worth $1.03M. The position accounts for 0.18% of the portfolio, ranked #81.

WESPAC Advisors SoCal first reported a position in LLY in Q4 2015 and has held it in 15 quarters since. The position peaked at $14.8M in Q3 2024. 1,669 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • WESPAC Advisors SoCal held 858 shares of Eli Lilly worth $1.03M as of Q2 2026.
  • WESPAC Advisors SoCal bought 185 Eli Lilly shares in Q2 2026, an estimated $189K.
  • Eli Lilly made up 0.18% of WESPAC Advisors SoCal's portfolio in Q2 2026, its #81 holding.
  • WESPAC Advisors SoCal first reported a position in Eli Lilly in Q4 2015 and has held it in 15 quarters since.
  • WESPAC Advisors SoCal's Eli Lilly position peaked at $14.8M in Q3 2024.
  • 1,669 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on WESPAC Advisors SoCal's 13F filing for Q2 2026, filed 16 Jul 2026.